Johnson & Johnson unveils first clinical data for prostate cancer drug JNJ-6143 at ESMO 2026

Bitget2026/10/23 12:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Johnson & Johnson will present more than 25 solid-tumor abstracts at the 2026 ESMO Congress, including first clinical results for JNJ-6143.
The investigational oral prostate cancer drug’s safety and efficacy findings will guide dose selection following the December 2025 acquisition of Halda Therapeutics.
Late-breaking Phase 3 PROTEUS results will assess perioperative Erleada treatment against surgery alone in high-risk localized or locally advanced prostate cancer.
Initial OrigAMI-4 findings show encouraging tumor responses with Rybrevant Faspro combined with pembrolizumab and carboplatin in first-line recurrent or metastatic head-and-neck cancer.
A separate indirect comparison found improved survival with Rybrevant Faspro monotherapy versus real-world therapies in previously treated head-and-neck cancer; results await presentation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Johnson & Johnson unveils first clinical data for prostate cancer drug JNJ-6143 at ESMO 2026

You may also like

Crypto prices